Companies: 10,795·Total market cap: $144.5T
60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc.

SXTPNASDAQHealthcare● Active
$1.43
+$0.00(+0.00%)
Market Cap$1153367
P/E Ratio
52W High$11.84
52W Low$1.29

60 Degrees Pharmaceuticals, Inc. (SXTP) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

sxtp · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for 60 Degrees Pharmaceuticals, Inc. (SXTP) measures how much investors pay for each dollar of the company's trailing earnings. SXTP's current PE ratio of N/A is calculated by dividing its stock price of $1.43 by its TTM earnings per share of -$4.39.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2026 est. EPS $-3.29
Based on 1 analyst
EPS (TTM)
-$4.39
TTM · diluted EPS
PEG Ratio
-0.00
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · 60 Degrees Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2020 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc.You
SXTP
$1MN/A-$4.39
Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc
BDRX
$1MN/A-$113.82
Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd.
CANF
$2MN/A-$12.02
Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics, Inc.
CLDI
$1MN/A-$4.63
Clearmind Medicine Inc.
Clearmind Medicine Inc.
CMND
$4MN/A-$3.03
CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals, Inc.
CNSP
$3MN/A-$35.75
GRI Bio, Inc.
GRI Bio, Inc.
GRI
$0MN/A-$121.80

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 6 of 6 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-10.99
2024-12-31
FY2024
$-69.93
2023-12-31
FY2023
$-3.80
2022-12-31
FY2022
$-4.28
2021-12-31
FY2021
$-2.94
2020-12-31
FY2020
$-2.10

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for 60 Degrees Pharmaceuticals, Inc. (SXTP) measures how much investors pay for each dollar of the company's trailing earnings. SXTP's current PE ratio of N/A is calculated by dividing its stock price of $1.43 by its TTM earnings per share of -$4.39.

PE Ratio = Stock Price ÷ EPS (TTM)
= $1.43 ÷ -$4.39 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

SXTP pe ratio · 6 questions

SXTP's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.43 and TTM EPS of -$4.39. Data sourced from Financial Modeling Prep via SXTP's SEC 10-K and 10-Q filings.

SXTP PE ratioWhat is SXTP PE ratioCurrent PE ratio of SXTPSXTP PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · 60 Degrees Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09